Spots Global Cancer Trial Database for KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
Official Title: KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
Study ID: NCT05635591
Conditions
Study Description
Brief Summary: The primary objectives of this study is to evaluate the tolerability and safety of KSD-101 in Patients with EBV-associated haematologic neoplasms, observe the dose-limiting toxicity (DLT) and and to explore the maximum tolerated dose (MTD).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Li Chunrui, Wuhan, Hubei, China
Contact Details
Name: Li Chunrui
Affiliation: Tongji Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
